{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:21:48Z","timestamp":1793161308157,"version":"4.5.0"},"reference-count":49,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>The optimal pharmacologic thromboprophylaxis agent after total hip and total knee arthroplasty is uncertain and consensus is lacking. Quantifying the risk of postoperative venous thromboembolism (VTE) and bleeding and evaluating comparative effectiveness and safety of the thromboprophylaxis strategies can inform care.<\/jats:p><\/jats:sec>Objective<\/jats:title>To quantify risk factors for postoperative VTE and bleeding and compare patient outcomes among pharmacological thromboprophylaxis agents used after total hip and knee arthroplasty.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This retrospective cohort study used data from a large health care claims database. Participants included patients in the United States with hip or knee arthroplasty and continuous insurance enrollment 3 months prior to and following their surgical procedure. Patients were excluded if they received anticoagulation before surgery, received no postsurgical pharmacological thromboprophylaxis, or had multiple postsurgery thromboprophylactic agents. In a propensity-matched analysis, patients receiving a direct oral anticoagulant (DOAC) were matched with those receiving aspirin.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Aspirin, apixaban, rivaroxaban, enoxaparin, or warfarin.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was 30-day cumulative incidence of postdischarge VTE. Other outcomes included postdischarge bleeding.<\/jats:p><\/jats:sec>Results<\/jats:title>Among 29\u202f264 patients included in the final cohort, 17\u202f040 (58.2%) were female, 27\u202f897 (95.2%) had inpatient admissions with median (IQR) length of stay of 2 (1-2) days, 10\u202f948 (37.4%) underwent total hip arthroplasty, 18\u202f316 (62.6%) underwent total knee arthroplasty; and median (IQR) age was 59 (55-63) years. At 30 days, cumulative incidence of VTE was 1.19% (95% CI, 1.06%-1.32%) and cumulative incidence of bleeding was 3.43% (95% CI, 3.22%-3.64%). In the multivariate analysis, leading risk factors associated with increased VTE risk included prior VTE history (odds ratio [OR], 5.94 [95% CI, 4.29-8.24]), a hereditary hypercoagulable state (OR, 2.64 [95% CI, 1.32-5.28]), knee arthroplasty (OR, 1.65 [95% CI, 1.29-2.10]), and male sex (OR, 1.34 [95% CI, 1.08-1.67]). In a propensity-matched cohort of 7844 DOAC-aspirin pairs, there was no significant difference in the risk of VTE in the first 30 days after the surgical procedure (OR, 1.14 [95% CI, 0.82-1.59]), but postoperative bleeding was more frequent in patients receiving DOACs (OR, 1.36 [95% CI, 1.13-1.62]).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study of patients who underwent total hip or total knee arthroplasty, underlying patient risk factors, but not choice of aspirin or DOAC, were associated with postsurgical VTE. Postoperative bleeding rates were lower in patients prescribed aspirin. These results suggest that thromboprophylaxis strategies should be patient-centric and tailored to individual risk of thrombosis and bleeding.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.45883","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T16:31:03Z","timestamp":1701448263000},"page":"e2345883","source":"Crossref","is-referenced-by-count":104,"title":["Venous Thromboembolism in Total Hip and Total Knee Arthroplasty"],"prefix":"10.1001","volume":"6","author":[{"given":"Samantha J.","family":"Simon","sequence":"first","affiliation":[{"name":"Research Department, New England Baptist Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rushad","family":"Patell","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hematologic Malignancies, Beth Israel Deaconess Medical Center, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Zwicker","sequence":"additional","affiliation":[{"name":"Hematology Service, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruv S.","family":"Kazi","sequence":"additional","affiliation":[{"name":"Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Hollenbeck","sequence":"additional","affiliation":[{"name":"Research Department, New England Baptist Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"issue":"9","key":"zoi231334r1","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.3899\/jrheum.170990","article-title":"Rates of total joint replacement in the United States: future projections to 2020-2040 using the national inpatient sample.","volume":"46","author":"Singh","year":"2019","journal-title":"J Rheumatol"},{"issue":"4","key":"zoi231334r2","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s11239-014-1078-1","article-title":"Platelet aggregation and coagulation factors in orthopedic surgery.","volume":"38","author":"Oberweis","year":"2014","journal-title":"J Thromb Thrombolysis"},{"issue":"19","key":"zoi231334r3","doi-asserted-by":"publisher","first-page":"698","DOI":"10.5435\/JAAOS-D-17-00235","article-title":"Trends in deep vein thrombosis prophylaxis and deep vein thrombosis rates after total hip and knee arthroplasty.","volume":"26","author":"Bawa","year":"2018","journal-title":"J Am Acad Orthop Surg"},{"issue":"7","key":"zoi231334r4","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2106\/00004623-197355070-00016","article-title":"\u201cDelayed\u201d prophylactic anticoagulation: a study of results and complications in 2,012 total hip arthroplasties.","volume":"55","author":"Coventry","year":"1973","journal-title":"J Bone Joint Surg Am"},{"issue":"3","key":"zoi231334r5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1586\/erp.11.15","article-title":"Economic impact of venous thromboembolism after hip and knee arthroplasty: potential impact of rivaroxaban.","volume":"11","author":"Friedman","year":"2011","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"5","key":"zoi231334r6","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1503\/cjs","article-title":"Impact of venous thromboembolism on clinical management and therapy after hip and knee arthroplasty.","volume":"54","author":"Fisher","year":"2011","journal-title":"Can J Surg"},{"issue":"4","key":"zoi231334r7","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1055\/s-0039-1677732","article-title":"Reduction in mortality following elective major hip and knee surgery: a systematic review and meta-analysis.","volume":"119","author":"Xu","year":"2019","journal-title":"Thromb Haemost"},{"issue":"2","key":"zoi231334r8","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1538-7836.2010.04155.x","article-title":"Incidence rates for thromboembolic, bleeding and hepatic outcomes in patients undergoing hip or knee replacement surgery.","volume":"9","author":"Lanes","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"21","key":"zoi231334r9","doi-asserted-by":"publisher","first-page":"8062","DOI":"10.1002\/cam4.v9.21","article-title":"Cancer associated thrombosis and mortality in patients with cancer stratified by khorana score risk levels.","volume":"9","author":"Khorana","year":"2020","journal-title":"Cancer Med"},{"issue":"9","key":"zoi231334r10","doi-asserted-by":"publisher","DOI":"10.3390\/medicina56090416","article-title":"An update on venous thromboembolism rates and prophylaxis in hip and knee arthroplasty in 2020.","volume":"56","author":"Santana","year":"2020","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"zoi231334r11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12891-015-0470-0","article-title":"Risk factors for venous thromboembolism of total hip arthroplasty and total knee arthroplasty: a systematic review of evidences in ten years.","volume":"16","author":"Zhang","year":"2015","journal-title":"BMC Musculoskelet Disord"},{"issue":"6","key":"zoi231334r12","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00402-015-2208-8","article-title":"Risk factors for venous thromboembolism after total hip and total knee arthroplasty: a meta-analysis.","volume":"135","author":"Zhang","year":"2015","journal-title":"Arch Orthop Trauma Surg"},{"issue":"5","key":"zoi231334r13","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/00063198-200209000-00004","article-title":"Risk factors for venous thromboembolism after total hip and knee replacement surgery.","volume":"8","author":"White","year":"2002","journal-title":"Curr Opin Pulm Med"},{"issue":"2 Suppl","key":"zoi231334r14","doi-asserted-by":"publisher","first-page":"e278S","DOI":"10.1378\/chest.11-2404","article-title":"Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.","volume":"141","author":"Falck-Ytter","year":"2012","journal-title":"Chest"},{"issue":"3","key":"zoi231334r15","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/rth2.12323","article-title":"What\u2019s new in VTE risk and prevention in orthopedic surgery.","volume":"4","author":"Kahn","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"zoi231334r16","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jor.2017.08.002","article-title":"Comparison of postoperative complications after total hip arthroplasty among patients receiving aspirin, enoxaparin, warfarin, and factor Xa inhibitors.","volume":"14","author":"Agaba","year":"2017","journal-title":"J Orthop"},{"issue":"8","key":"zoi231334r17","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1712746","article-title":"Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty.","volume":"378","author":"Anderson","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi231334r18","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1001\/jamainternmed.2019.6108","article-title":"Clinical effectiveness and safety of aspirin for venous thromboembolism prophylaxis after total hip and knee replacement: a systematic review and meta-analysis of randomized clinical trials.","volume":"180","author":"Matharu","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"3","key":"zoi231334r19","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1182\/bloodadvances.2017010694","article-title":"Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation.","volume":"2","author":"Shah","year":"2018","journal-title":"Blood Adv"},{"issue":"4","key":"zoi231334r20","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1111\/jth.15654","article-title":"Postoperative bleeding complications in patients with hemophilia undergoing major orthopedic surgery: a prospective multicenter observational study.","volume":"20","author":"Kleiboer","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"1","key":"zoi231334r21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13018-015-0188-6","article-title":"Transfusions and blood loss in total hip and knee arthroplasty: a prospective observational study.","volume":"10","author":"Carling","year":"2015","journal-title":"J Orthop Surg Res"},{"issue":"6","key":"zoi231334r22","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s11739-016-1414-x","article-title":"Perioperative coagulation assessment of patients undergoing major elective orthopedic surgery.","volume":"11","author":"Spiezia","year":"2016","journal-title":"Intern Emerg Med"},{"issue":"23","key":"zoi231334r23","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1182\/bloodadvances.2019000975","article-title":"American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients.","volume":"3","author":"Anderson","year":"2019","journal-title":"Blood Adv"},{"issue":"12","key":"zoi231334r24","doi-asserted-by":"publisher","first-page":"768","DOI":"10.5435\/00124635-201112000-00007","article-title":"Preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty.","volume":"19","author":"Mont","year":"2011","journal-title":"J Am Acad Orthop Surg"},{"issue":"5","key":"zoi231334r25","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/bjh.v186.5","article-title":"The National VTE Exemplar Centres Network response to implementation of updated NICE guidance: venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89).","volume":"186","author":"Gee","year":"2019","journal-title":"Br J Haematol"},{"key":"zoi231334r26","doi-asserted-by":"publisher","first-page":"180","DOI":"10.2106\/JBJS.21.01529","article-title":"Recommendations from the ICM-VTE: hip & knee.","volume":"104","author":"The ICM-VTE Hip & Knee Delegates","year":"2022","journal-title":"J Bone Joint Surg Am"},{"key":"zoi231334r27","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.artd.2021.06.015","article-title":"Time for an update? a look at current guidelines for venous thromboembolism prophylaxis after hip and knee arthroplasty and hip fracture.","volume":"10","author":"Muscatelli","year":"2021","journal-title":"Arthroplast Today"},{"issue":"11","key":"zoi231334r28","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1302\/0301-620X.99B11.BJJ-2017-0337.R2","article-title":"Aspirin and the prevention of venous thromboembolism following total joint arthroplasty: commonly asked questions.","volume":"99-B","author":"Azboy","year":"2017","journal-title":"Bone Joint J"},{"issue":"10","key":"zoi231334r29","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1007\/s11606-019-05122-3","article-title":"Aspirin compared with anticoagulation to prevent venous thromboembolism after knee or hip arthroplasty: a large retrospective cohort study.","volume":"34","author":"Baumgartner","year":"2019","journal-title":"J Gen Intern Med"},{"issue":"9212","key":"zoi231334r30","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S0140-6736(00)02110-3","article-title":"Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: pulmonary embolism prevention (PEP) trial.","volume":"355","year":"2000","journal-title":"Lancet"},{"issue":"2","key":"zoi231334r31","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s11239-019-01885-y","article-title":"Assessing the accuracy of ICD-10 codes for identifying acute thromboembolic events among patients receiving anticoagulation therapy.","volume":"48","author":"Lawrence","year":"2019","journal-title":"J Thromb Thrombolysis"},{"issue":"5","key":"zoi231334r32","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1111\/bjh.2019.185.issue-5","article-title":"Risk of hospitalised bleeding in comparisons of oral anticoagulant options for the primary treatment of venous thromboembolism.","volume":"185","author":"Lutsey","year":"2019","journal-title":"Br J Haematol"},{"issue":"4","key":"zoi231334r34","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-Value.","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"issue":"5","key":"zoi231334r35","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1097\/EDE.0000000000000864","article-title":"Website and R package for computing E-values.","volume":"29","author":"Mathur","year":"2018","journal-title":"Epidemiology"},{"issue":"5","key":"zoi231334r36","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/ije\/dyz261","article-title":"Use of e-values for addressing confounding in observational studies-an empirical assessment of the literature.","volume":"49","author":"Blum","year":"2020","journal-title":"Int J Epidemiol"},{"issue":"1","key":"zoi231334r37","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.arth.2019.08.049","article-title":"Have venous thromboembolism rates decreased in total hip and knee arthroplasty?","volume":"35","author":"Warren","year":"2020","journal-title":"J Arthroplasty"},{"issue":"7S","key":"zoi231334r40","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1016\/j.arth.2021.01.080","article-title":"Current practice trends in primary hip and knee arthroplasties among members of the American Association of Hip and Knee Surgeons: an update during the COVID-19 pandemic.","volume":"36","author":"Abdel","year":"2021","journal-title":"J Arthroplasty"},{"issue":"11","key":"zoi231334r41","doi-asserted-by":"publisher","first-page":"800","DOI":"10.7326\/0003-4819-158-11-201306040-00004","article-title":"Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial.","volume":"158","author":"Anderson","year":"2013","journal-title":"Ann Intern Med"},{"issue":"8","key":"zoi231334r42","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/jama.2022.13416","article-title":"Effect of aspirin vs enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: the CRISTAL randomized trial.","volume":"328","author":"Sidhu","year":"2022","journal-title":"JAMA"},{"issue":"9","key":"zoi231334r44","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/jhm.v9.9","article-title":"Aspirin versus anticoagulation for prevention of venous thromboembolism major lower extremity orthopedic surgery: a systematic review and meta-analysis.","volume":"9","author":"Drescher","year":"2014","journal-title":"J Hosp Med"},{"issue":"5","key":"zoi231334r45","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1002\/cpt.v109.5","article-title":"Randomized controlled trials versus real world evidence: neither magic nor myth.","volume":"109","author":"Eichler","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"zoi231334r46","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1007\/s11999-017-5394-6","article-title":"Venous thromboembolism prophylaxis after TKA: aspirin, warfarin, enoxaparin, or factor Xa inhibitors?","volume":"475","author":"Bala","year":"2017","journal-title":"Clin Orthop Relat Res"},{"issue":"1","key":"zoi231334r47","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1182\/hematology.2020000150","article-title":"Does aspirin prevent venous thromboembolism?","volume":"2020","author":"Diep","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"10","key":"zoi231334r48","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1161\/01.CIR.101.10.1206","article-title":"Aspirin.","volume":"101","author":"Awtry","year":"2000","journal-title":"Circulation"},{"issue":"1","key":"zoi231334r49","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.thromres.2008.05.005","article-title":"Has the incidence of deep vein thrombosis in patients undergoing total hip\/knee arthroplasty changed over time? a systematic review of randomized controlled trials.","volume":"123","author":"Xing","year":"2008","journal-title":"Thromb Res"},{"key":"zoi231334r33","volume-title":"Scandinavian Journal of Rheumatology","author":"Molander"},{"key":"zoi231334r39","volume-title":"StatPearls","author":"Senst","year":"2022"},{"key":"zoi231334r38","unstructured":"Centers for Disease Control and Prevention. Data and statistics on venous thromboembolism. Published June 9, 2022. https:\/\/www.cdc.gov\/ncbddd\/dvt\/data.html"},{"key":"zoi231334r43","unstructured":"Pellegrini? V, Lambourne? C. Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement (PEPPER). ClinicalTrials.gov identifier: NCT02810704. Updated November 14, 2022. Accessed January 4, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02810704"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2812418\/simon_2023_oi_231334_1700596733.2243.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T16:31:07Z","timestamp":1701448267000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2812418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.45883","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]}}}